NASDAQ · MGTXHealthcareBiotechnology

MeiraGTx Holdings financials

$11.13+0.18%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$81.4M$33.3M$14.0M$15.9M$37.7M$15.6M$13.3M—
Gross profit$81.4M$33.3M$14.0M$15.9M$37.7M$15.6M$13.3M—
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%100.0%—
Operating income-$106.0M-$164.2M-$137.1M-$116.4M-$72.8M-$62.6M-$58.3M-$78.1M
Net income-$114.2M-$147.8M-$84.0M-$129.6M-$79.6M-$58.0M-$54.7M-$84.7M
Net margin−140.3%−444.1%−599.5%−814.2%−211.0%−372.6%−411.9%—
Diluted EPS$-1.42$-2.12$-1.49$-2.87$-1.80$-1.54$-1.65$-4.47
EBITDA-$93.4M-$151.4M-$123.3M-$107.6M-$64.9M-$58.4M-$56.0M-$76.1M
Operating cash flow-$46.4M-$104.5M-$105.4M-$73.1M-$10.5M-$64.0M$20.8M-$58.8M
Free cash flow-$50.2M-$109.5M-$125.5M-$118.1M-$56.9M-$84.9M$11.9M-$70.0M
Diluted shares80.4M69.8M56.5M45.2M44.1M37.7M33.2M18.9M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$65.9M$103.7M$129.6M$115.5M$137.7M$209.5M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$107.4M$73.2M$72.1M$71.3M$953.0K$0.00
Total assets$244.4M$269.8M$326.7M$318.2M$320.2M$363.7M
Total liabilities$250.2M$201.9M$188.6M$200.5M$134.8M$125.1M
Shareholders' equity-$5.8M$67.8M$138.2M$117.7M$185.4M$238.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology